Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5425 - 5432 of 12092 results
First Circuit Rules That “Incorporation by Reference” of Collateral Description in UCC Financing Statements May Not Perfect Lien
February 14, 2019| Blog| Viewpoint
FAA Announces New UAS (Drone) Marking Rule
February 14, 2019| Alert| Viewpoint
Will MA Continue to Lead on Offshore Wind Development?
February 14, 2019| Blog| Viewpoint
Shifting Scrutiny of H-1B Visas Raises Eyebrows About Motive
February 14, 2019| News
Federal Trade Commission: No Changes to CAN-SPAM Rules
February 13, 2019| Blog| Viewpoint
A Tale of Two False Claims Act Settlements Involving EHR Vendors
February 13, 2019| Blog| Viewpoint
As CMS Lifts HHA Medicare Provider Enrollment Moratorium, States Continue to Limit HHA Licenses
February 12, 2019| Blog| Viewpoint
Time-Barred IPR Petitioners Have Separate Standing to Appeal PTAB Decisions
February 12, 2019| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|